Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGT-53 plus Gemcitabine/Nab-Paclitaxel in Metastatic Pancreatic Cancer
NCT02340117Phase 2Active, not recruiting
- Sponsor
- SynerGene Therapeutics, Inc.
- Start
- Jan 2015
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of SGT-53, sponsored by SynerGene Therapeutics, Inc.. Started Jan 2015; status: active, not recruiting.
02
Drugs
SGT-53
Beyond the preview
Go deeper on NCT02340117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02340117.